Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Pharmacist-led care pathway for type 2 diabetes in Alberta community pharmacies

Official title: Implementation and Evaluation of a Pharmacist-led Diabetes Care Pathway in Alberta Community Pharmacies.

Run by University of Alberta · NCT07339852 · Data updated 2026-11-12

This project will test whether a pharmacist-led care pathway in community pharmacies can help adults with type 2 diabetes and HbA1c above 7.0% lower their blood sugar and improve care compared with usual physician or nurse practitioner care.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment600 (estimated)
SponsorUniversity of Alberta
Academic / other
Locations1 site (Edmonton, Alberta)
StatusRecruiting
StartedOctober 13, 2025
Main results expectedOctober 1, 2026
Study endsOctober 1, 2026
Registry record updatedJanuary 14, 2026
Trial IDNCT07339852 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18 or older with type 2 diabetes whose HbA1c is above 7.0% and who can consent and attend follow-up visits are the intended participants.

Probably not a fit

People with type 1 or gestational diabetes, pregnant individuals, those already at HbA1c target under 7.0%, those with limited life expectancy or frailty, or those unable to consent or attend follow-ups are unlikely to benefit from participating.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults with type 2 diabetes whose HbA1c is not at target will be enrolled and receive a structured pharmacist-led diabetes care pathway in community pharmacies. Pharmacists will provide medication review, shared decision-making, education, monitoring and follow-up visits, and coordinate with patients' primary care providers. Outcomes will include changes in HbA1c and management of cardiovascular risk factors such as blood pressure and lipids, measured over scheduled follow-ups. Results will be compared to usual care to see if the pharmacist-led approach improves glucose control and care processes.

Why it matters

Potential benefit: If successful, this could make it easier for people with type 2 diabetes to reach target blood sugar levels and lower their risk of diabetes-related complications.

How similar studies have gone: Previous pharmacist-led interventions have shown modest to meaningful improvements in HbA1c and medication management, so this approach builds on existing evidence.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Individuals aged 18 years or older.
2. Individuals with type 2 diabetes.
3. Individuals with type 2 diabetes not reaching HbA1c target of under 7.0%

Exclusion Criteria:

1. Individuals with type 1 diabetes, gestational diabetes, or other forms of diabetes that are not type 2 diabetes.
2. Pregnant individuals.
3. Individuals at their HbA1c target (HbA1c under 7.0%) or those with a limited life expectancy, frailty, or lack hypoglycemic awareness (i.e., those with an A1c target above 7.0%) .
4. Individuals unable to provide consent or who are unwilling to attend follow-up visits.

Where it's running

  • University of Alberta
    Edmonton, Alberta, Canada
    Recruiting

Study contacts

  • Principal investigator: Ross Tsuyuki, BScPharm, PharmD, MSc — University of Alberta
  • Study coordinator: Stephanie Gysel, BScPharm, PharmD
  • Email: sgysel@ualberta.ca
  • Phone: 403-993-6678

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.